A pulsatile drug delivery system containing dexketoprofen trometamol was designed by combining immediate release and colon-targeted mini tablets into a capsule.
Both immediate release and colon-targeted mini tablets were prepared by wet granulation. Furthermore, colon-targeted mini tablets were coated with Eudragit L 100, Eudragit S 100, Eudragit RS 30D, and ethylcellulose (Surelease®) using Wurster and pan coating methods.
The optimum drug release of the system developed in the study was found to be mini tablets coated with 30% Eudragit S 100 on a 20% Surelease® subcoating for the purpose of colon targeting.
In the finished product, the immediate release part released the drug within the first hour, and less than 5% release was observed from the colon-targeted tablets in a 0.1 N HCl in 2 h. Then, less than 20% release occurred in the colon-targeted tablets up to 6 h in pH 6.8 phosphate buffer solution. The cumulative release rate reached 100% for up to 12 h. To our knowledge, it was the first time dexketoprofen trometamol was designed by combining both immediate release and colon-targeted mini tablets in a one dosage form.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Keerthi ML, Kiran RS, Rao VUM, Sannapu A, Dutt AG, Krishna KS. Pharmaceutical mini-tablets, its advantages, formulation possibilities and general evaluation aspects: a review. Int. J. Pharm. Sci. Rev. Res. 2014;28(1):214–21.
Lopes CM, Lobo JMS, Pinto JF, Costa P. Compressed mini-tablets as a biphasic delivery system. Int. J. Pharm. 2006;323:93–100.
Das S, Deshmukh R, Jha A. Role of natural polymers in the development of multiparticulate systems for colon drug targeting. Syst Rev Pharmacy. 2010;1(1):79–85.
Chourasia MK, Jain SK. Design and development of multiparticulate system for targeted drug delivery to colon. Drug Deliv. 2004;11(3):201–7.
Kibria G, Ul-Jalil R. The effect of the ratio of two acrylic polymers on the in vitro release kinetics of ketoprofen from pellets prepared by extrusion and spheronisation technique. Pak. J. Pharm. Sci. 2008;21(2):92–7.
Miranda HF, Sierralta F, Aranda N, Noriega V, Prieto JC. Pharmacological profile of dexketoprofen in orofacial pain. Pharmacol. Rep. 2016;68:1111–6.
Barbanoj MJ, Antonijoan RM, Gich I. Clinical pharmacokinetics of dexketoprofen. Clin Pharmacokinet. 2001;40(4):245–62.
Garcia-Arieta A, Gordon J, Gwaza L, Mangas-Sanjuan V, Álvarez C, Torrado JJ. Agitation rate and time for complete dissolution in bcs biowaivers based on investigation of a BCS biowaiver for dexketoprofen tablets. Mol. Pharmaceutics. 2015;12:3194–201.
Rudolph MW, Klein S, Beckert TE, Petereit HU, Dressman JB. A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur. J. Pharm. Biopharm. 2001;51:183–90.
Patel HP, Karwa P, Patel NJ. A novel approach to sustained Zolpidem tartrate release: Compressed mini-tablets. Int. J. Pharm. Sci. Rev. and Res. 2011;7(2):53–8.
Aleksovski A, Luštrik M, Šibanc R, Dreu R. Design and evaluation of a specific, bi-phase extended release system based on differently coated mini-tablets. Eur. J. Pharm. Sci. 2015;75:114–22.
Stubbe BG, De Smedt SC, Demeester J. “Programmed polymeric devices”for pulsed drug delivery. Pharm. Res. 2004;21:1732–40.
Gupta VK, Gnanarajan G, Kothiyal P. A review article on colonic targeted drug delivery system. The Pharma Innov. 2012;1(7):14–24.
Ghugarkar P, Kulat P, Swain K, Suggala V, Shaik D. Colon targeted drug delivery system: a review on primary and novel approaches. Int. J. Pharm. Sci. Res. 2015;6(7):2681–8.
Kumar P, Mishra B. Colon targeted drug delivery systems -an overview. Curr. Drug Deliv. 2008;5:186–98.
Krishnamachari Y, Madan P, Lin S. Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int. J. Pharm. 2007;338:238–47.
Yang L, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int. J. Pharm. 2002;235:1–15.
Ibekwe VC, Fadda HM, McConnell EL, Khela MK, Evans DF, Basit AW. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res. 2008;25(8):1828–35.
Ibekwe VC, Fadda HM, Parsons GE, Basit AW. A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery. Int. J. Pharm. 2006;308:52–60.
Leopold CS, Eikeler D. Eudragit E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD). J Drug Target. 1998;6(2):85–94.
Patra N, Priya R, Swain S, Jena GK, Panigrahi KC, Ghose D. Pharmaceutical significance of Eudragit: A review. Future J. Pharm. Sci. 2017;3:33–45.
McConnell EL, Short MD, Basit AW. An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man. J. Control. Release. 2008;130(2):154–60.
Colorcon Limited. Surelease® Ethylcellulose Dispersion Type B NF. [accessed 2018 July 17]. https://www.colorcon.com/products-formulation/all-products/film-coatings/sustained-release/surelease.
Leuva VR, Patel BG, Chaudhary DJ, Patel JN, Modasiya MMK. Oral colon-specific drug delivery system. J Pharm Res. 2012;5(4):2293–7.
Biswall PK, Kumar A, Bhadouriya AS. Design and evolution of colon specific drug delivery system. Int. J. Pharmaceut. Chem. Biol. Sc. 2013;3(1):150–67.
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry, dissolution testing and acceptance criteria for immediate-release solid oral dosage form drug products containing high solubility drug substances. August 2018, p 15.
United States Pharmacopeia 41, National Formulary 36, Rockville MD USA: United States Pharmacopeial Convention 2018.
Patel MM, Patel SL, Bhadani MN, Shah TJ, Amin AF. A synchronous colon-specific drug delivery system for orally administered mesalamine. Acta Pharm Sci. 2009;51:251–60.
Modified and Immediate Release Formulations of Memantine. Patent No. US 2007/0065512 A1. Forest Laboratories, Inc.
Akhgari A, Garekani HA, Sadeghi F, Azimaie M. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery. Int. J. Pharm. 2005;305:22–30.
Forest Laboratories, Inc. Modified and Immediate Release Formulations of Memantine. United States Patents, US 2007/0065512 A1.
Patel MM, Shah TJ, Amin AF, Shah NN. Design, development, and optimization of a novel time and pH-dependent colon targeted drug delivery system. Pharm Dev Technol. 2009;14:62–9.
Patel MM, Amin AF. Design and optimization of colon-targeted system of theophylline for chronotherapy of nocturnal asthma. J. Pharm. Sci. 2011;100(5):1760–72.
This research was supported by DEVA Holding, Turkey.
Conflict of Interest
The authors declare that they have no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ugurlu, T., Ilhan, E. Development and In Vitro Evaluation of a Novel Pulsatile Drug Delivery System Containing Dexketoprofen Trometamol. J Pharm Innov (2020). https://doi.org/10.1007/s12247-020-09452-2
- Dexketoprofen trometamol
- Mini tablet
- Colon targeting
- Rheumatoid arthritis
- Pulsatile release